TP53 and gastric cancer: RUNX2 has also been shown to be significantly overexpressed in platinum-chemotherapy-resistant gastric cancer cells and tissues, and RUNX2 reduces the response of gastric cancer to chemotherapeutic drugs by negatively regulating p53-mediated apoptosis [180].